Key Points
- CEO Martine Rothblatt sold 9,500 United Therapeutics shares at an average price of $548.95, generating approximately $5.22 million. She retained 324,443 shares valued at about $178.1 million.
- United Therapeutics reported quarterly EPS of $7.27, beating estimates of $6.86, while revenue of $783.3 million fell short of expectations and declined 1.9% year over year.
- Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $627.31; institutional investors own 94.08% of the company.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction on Wednesday, October 7th. The shares were sold at an average price of $548.95, for a total transaction of $5,215,025.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares in the company, valued at $178,102,984.85. The trade was a 2.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
United Therapeutics Price Performance
UTHR stock opened at $532.78 on Friday. The company has a market cap of $22.85 billion, a price-to-earnings ratio of 19.06, a price-to-earnings-growth ratio of 2.73 and a beta of 0.49. The company has a fifty day moving average price of $511.37 and a 200 day moving average price of $539.93. United Therapeutics Corporation has a 12 month low of $409.07 and a 12 month high of $609.35.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. During the same period last year, the firm posted $6.41 EPS. United Therapeutics's revenue for the quarter was down 1.9% on a year-over-year basis. As a group, analysts anticipate that United Therapeutics Corporation will post 26.21 earnings per share for the current year.
Analyst Ratings Changes
Several research firms have commented on UTHR. Morgan Stanley upped their price objective on United Therapeutics from $515.00 to $566.00 and gave the company an "equal weight" rating in a research note on Wednesday. Royal Bank Of Canada upped their price target on United Therapeutics from $677.00 to $708.00 and gave the stock an "outperform" rating in a research note on Thursday. Weiss Ratings cut United Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a research report on Thursday, August 27th. JPMorgan Chase & Co. raised their price objective on United Therapeutics from $685.00 to $687.00 and gave the company an "overweight" rating in a research note on Thursday, July 23rd. Finally, Bank of America cut their target price on shares of United Therapeutics from $620.00 to $613.00 and set a "neutral" rating for the company in a research report on Friday, July 10th. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $627.31.
Check Out Our Latest Report on United Therapeutics
Institutional Investors Weigh In On United Therapeutics
A number of hedge funds have recently bought and sold shares of the business. Apella Capital LLC grew its position in shares of United Therapeutics by 27.0% in the 3rd quarter. Apella Capital LLC now owns 451 shares of the biotechnology company's stock worth $246,000 after acquiring an additional 96 shares in the last quarter. Toth Financial Advisory Corp grew its position in shares of United Therapeutics by 100.0% during the third quarter. Toth Financial Advisory Corp now owns 100 shares of the biotechnology company's stock worth $54,000 after acquiring an additional 50 shares during the last quarter. Whalen Wealth Management Inc. grew its position in United Therapeutics by 18.4% in the 3rd quarter. Whalen Wealth Management Inc. now owns 1,118 shares of the biotechnology company's stock worth $606,000 after purchasing an additional 174 shares during the last quarter. QRG Capital Management Inc. grew its holdings in United Therapeutics by 3.5% in the 2nd quarter. QRG Capital Management Inc. now owns 3,476 shares of the biotechnology company's stock worth $1,883,000 after buying an additional 116 shares in the last quarter. Finally, Envestnet Portfolio Solutions Inc. increased its holdings in shares of United Therapeutics by 1.8% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 3,445 shares of the biotechnology company's stock valued at $1,867,000 after purchasing an additional 60 shares during the period. Institutional investors and hedge funds own 94.08% of the company's stock.
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company's products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment.
United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
